Triple-negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy 1-3 . BET bromodomain inhibitors, which have shown efficacy in several models of cancer 4-6 , have not been evaluated in TNBC. These inhibitors displace BET bromodomain proteins such as BRD4 from chromatin by competing with their acetyl-lysine recognition modules, leading to inhibition of oncogenic transcriptional programs 7-9 . Here we report the preferential sensitivity of TNBCs to BET bromodomain inhibition in vitro and in vivo, establishing a rationale for clinical investigation and further motivation to understand mechanisms of resistance. In paired cell lines selected for acquired resistance to BET inhibition from previously sensitive TNBCs, we failed to identify gatekeeper mutations, new driver events or drug pump activation. BET-resistant TNBC cells remain dependent on wild-type BRD4, which supports transcription and cell proliferation in a bromodomain-independent manner. Proteomic studies of resistant TNBC identify strong association with MED1 and hyper-phosphorylation of BRD4 attributable to decreased activity of PP2A, identified here as a principal BRD4 serine phosphatase. Together, these studies provide a rationale for BET inhibition in TNBC and present mechanism-based combination strategies to anticipate clinical drug resistance.
Triple-negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy 1-3 . BET bromodomain inhibitors, which have shown efficacy in several models of cancer 4-6 , have not been evaluated in TNBC. These inhibitors displace BET bromodomain proteins such as BRD4 from chromatin by competing with their acetyl-lysine recognition modules, leading to inhibition of oncogenic transcriptional programs [7] [8] [9] . Here we report the preferential sensitivity of TNBCs to BET bromodomain inhibition in vitro and in vivo, establishing a rationale for clinical investigation and further motivation to understand mechanisms of resistance. In paired cell lines selected for acquired resistance to BET inhibition from previously sensitive TNBCs, we failed to identify gatekeeper mutations, new driver events or drug pump activation. BET-resistant TNBC cells remain dependent on wild-type BRD4, which supports transcription and cell proliferation in a bromodomain-independent manner. Proteomic studies of resistant TNBC identify strong association with MED1 and hyper-phosphorylation of BRD4 attributable to decreased activity of PP2A, identified here as a principal BRD4 serine phosphatase. Together, these studies provide a rationale for BET inhibition in TNBC and present mechanism-based combination strategies to anticipate clinical drug resistance.
To explore non-oncogene addiction to BRD4 in breast cancer, we studied a series of BET bromodomain inhibitors (BBI) across breast cell lines reflecting transcriptionally defined breast cancer subtypes: luminal, HER2 + and TNBC 2,10 , as well as MCF10A and MCF12A basal/ mesenchymal immortalized mammary epithelial cells (Supplementary Table 1 ). Potent inhibitory effects were observed preferentially in TNBC lines, compared to more resistant luminal lines (Fig. 1a ). Analysis of potency of drug response and subtype or known driver mutations identified the basal subtype as the only significant association (P = 0.0475) (Supplementary Table 1 and data not shown). BRD4 dependency was confirmed by RNA interference and phenocopied BBI (Extended Data Fig. 1a-c ). JQ1 or BRD4 knockdown induced growth inhibition and resulted in G1 arrest and apoptosis (Extended Data Fig. 1d -g). Expression of factors described to mediate JQ1 effect (MYC) or required for TNBC growth (JAK2/STAT3) showed no clear association with JQ1 sensitivity (Extended Data Fig. 1h and Extended Data Fig. 2a, b ). JQ1 treatment of TNBC cells induced significant morphologic changes consistent with induction of senescence, confirmed by β-galactosidase staining and luminal differentiation evidenced by changes in the expression of basal and luminal markers (Extended Data Fig. 2c, d and Fig. 1b ).
Extending the translational significance of these findings, we evaluated the ability of JQ1 to inhibit tumour growth in murine TNBC xenografts. Two-week treatment efficiently inhibited established tumour growth from SUM159 and MDA-MB-231 lines, and patient-derived primary human TNBC xenografts ( Fig. 1c and Extended Data Fig. 2e , f). Downregulation of BRD4 using two independent TET-inducible short hairpin RNAs produced even more pronounced effects, leading to complete tumour regression and failure to regrow even after discontinuing doxycycline treatment ( Fig. 1c and Extended Data Fig. 2g ). Evidence of BBI-induced basal-to-luminal differentiation was confirmed in vivo (Extended Data Fig. 2f, h) .
Using integrated epigenomic analysis (Supplementary Table 2 ), we identified the direct transcriptional targets of BBI in TNBC. BBI binding was identified at active promoter and enhancer regions using ChemSeq 11 for biotinylated JQ1 (Bio-JQ1) enrichment and chromatin immunoprecipitation followed by sequencing (ChIP-seq) for acetyl-histone (H3K27ac) and BRD4 enrichment, with the three marks showing near perfect co-localization ( Fig. 1d and Extended Data Fig. 3a ). BBI efficiently displaced chromatin-bound BRD4 in treated SUM159 ( Fig. 1e and Extended Data Fig. 3b ) and in SUM149 cells (Extended Data Fig. 3c ). To identify biologically relevant, direct targets of BBI in SUM159 and SUM149 cells, we quantified binding of Bio-JQ1 and BRD4 genome-wide and found strong enrichment at 219 and 159 super-enhancers, respectively ( Fig. 1f , Extended Data Fig. 3d and Supplementary Table 3 ) 8, 9, 12, 13 . Transcription factors with known roles in breast cancer, such as POU5F1B/MYC 14 and HIF1α 15 , were evident among top super-enhancer-associated genes in both lines. Kinetic effects of JQ1 treatment on gene expression demonstrated preferential super-enhancer-associated gene downregulation ( Fig. 1g and Extended Data Fig. 3e, f) . Expression changes were observed within 3 h after JQ1 treatment and, as expected, more genes were significantly down-than upregulated (Extended Data Fig. 3g-j and Supplementary Table 4 ). Unsupervised Metacore 16 analysis of JQ1-affected target pathways revealed downregulation of regulatory and effector genes in antiapoptotic and JAK/STAT signalling pathways (Extended Data Fig. 3k ).
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These data support selective disruption of super-enhancer-associated genes by JQ1, leading to deregulation of coordinated transcriptional pathways involved in cell proliferation, invasion and survival.
Dissecting resistance to targeted therapy is critical to elucidate mechanisms of drug and target action, and to suggest approaches to treat or anticipate drug resistance in patients. Therefore, we established BBI-resistant TNBC cell lines by long-term culture of both SUM159 and SUM149 cells in escalating JQ1 doses. Low (0.5 μM) and high (2.0 μM) doses of JQ1 severely impaired proliferation of parental SUM159 and SUM149 lines, reducing viable cells after 6 days ( Fig. 2a and Extended Data Fig. 3l ). In contrast, JQ1-resistant cells (SUM159R and SUM149R) proliferated linearly, even in high JQ1 doses (20 μM) ( Fig. 2a and Extended Data Fig. 3l ). BBI-resistance is not attributable to drug export, as MDR1 and other transporters are not transcriptionally upregulated (Extended Data Fig. 4a ), co-incubation with MDR1 inhibitors (verapamil) had no effect (Extended Data Fig. 4b ), and structurally divergent BBIs are equally inactive as JQ1 ( Fig. 2b ). Further support is provided by the equivalent chromatin engagement of BRD4 in sensitive and resistant cells, demonstrated by binding with Bio-JQ1 (Extended Data Fig. 4c ). Notably, BBI-resistant TNBC cells retain sensitivity to compounds from orthogonal active drug classes, such as MCF-10A  MDA-MB-453   BT-549  DU4475  MDA-MB-468   HCC-38  Hs578T  CAL-851  HCC1-806  SUM159  MDA-MB-157   SUM149  MCF-12A  HCC-1187  HCC-1569  HCC-1428   SW527  SUM-52PE  CAL-120  HCC-1937  HCC-1143  CAL-148  HCC-3153  MDA-MB-231   MCF-7  MDA-MB-134-VI   HCC-70  CAMA-1  BT-474  SUM1315M02  SUM190PT  SK-BR-3  CAL-51  ZR-75-1  ZR-75-30  EL-12-58  SUM185PE  MDA-MB-436  HCC-1395   T- Letter reSeArCH CXCR2 and JAK2 inhibitors 17 , establishing specific resistance to BBIs (Extended Data Fig. 4d ). Adaptive drug resistance was not attributable to outgrowth of a minor subpopulation of pre-existing resistant cells, as 10 independent single-cell-derived clones showed similar resistance profiles to pooled SUM159R cells (Extended Data Fig. 4e ). Similar results were obtained in vivo, as SUM159R-derived xenografts were JQ1-unresponsive (Extended Data Fig. 4f ). In all resistant TNBC populations studied, exome sequencing failed to identify alterations in BET bromodomain-encoding genes (for example, gatekeepers) or known driver genes (parallel pathway activation) (Supplementary Table 5 ). Absent new genetic alterations, we explored the plausibility of an epigenomic mechanism of resistance. Differential enhancer analysis revealed a significant gain of super-enhancers in resistant SUM159R cells ( Fig. 2c and Supplementary Table 6 ). The gain of Bio-JQ1 super enhancers was associated with enrichment for BRD4 binding to these genomic loci ( Fig. 2d ) and increased transcription of associated genes ( Fig. 2e ). An upstream/intragenic region of H3K27ac at the BCL-xL locus featured prominently among top gained super enhancers in SUM159R ( Fig. 2f) , consistent with increased BCL-xL messenger RNA and protein expression in resistant cells (Supplementary Table 7 , Extended Data Fig. 4g ). Functionally, cells with acquired resistance to BBI featured a concordant switch in JQ1 anti-apoptotic response based on dynamic BH3 profiling 18, 19 (Extended Data Fig. 4h ).
Observing emergent enhancers in resistant cells, we assessed whether BBI-resistant TNBC cells retained non-oncogene addiction to BRD4. Notably, we observed loss of SUM159R cell viability upon BRD4 knockdown (Extended Data Fig. 5a, b ). Together these studies establish persistence of BRD4 addiction despite resistance to bromodomain inhibition, establishing the plausibility of bromodomain-independent recruitment of BRD4 to enhancers in BBI-resistant TNBCs. To test this hypothesis, we performed BRD4 ChIP-seq on sensitive and resistant cells with and without JQ1. JQ1 neither displaced BRD4 from chromatin in SUM159R ( Fig. 2g ), nor meaningfully influenced epigenome structure by H3K27ac ChIP-seq (Extended Data Fig. 5c -g). Notably, several luminal markers (FOXA1, CD24, and luminal cytokeratins) were elevated in SUM159R cells in cell culture and in vivo (Extended Data Fig. 5h , i), supporting a model whereby resistance arises via essential BRD4 recruitment to chromatin in a bromodomain-independent manner. Similar observations were made in SUM149R cells and in TNBC cells inherently resistant to JQ1 (Extended Data Fig. 3h -j; Extended Data Fig. 6a-d ), suggesting a general mechanism of epigenomic resistance to BBI.
To disclose potential differences in BRD4-associated complexes between sensitive and resistant SUM159 cells, we performed quantitative proteomics using RIME (rapid immunoprecipitation mass spectrometry of endogenous proteins) 20 with and without JQ1. Analysis of BRD4-associated proteins identified relative enrichment of MED1 and BRD3 in JQ1-treated resistant cells ( Fig. 3a , Extended Data Fig. 7 and Supplementary Table 8 ). BRD4 immunoprecipitation followed by immunoblot for MED1 and BRD3 revealed that JQ1 efficiently displaced BRD4 from MED1 in sensitive cells, but not in resistant cells (Fig. 3b ), a result confirmed in SUM149 and BBI-resistant SUM149R, as well as inherently resistant TNBC and luminal lines (Extended Data Fig. 8a ). Although elevated BRD3 abundance was observed in SUM159R cells, increased association of BRD4 and BRD3 was not confirmed by immunoblot ( Fig. 3b ). To assess functionally whether increased recruitment of BRD4 to chromatin by MED1 underlies resistance to JQ1, we expressed an exogenous bromodomaininactivated mutant (BDmut) with concomitant knockdown of endogenous BRD4 (Extended Data Fig. 8b , c). Downregulation of endogenous BRD4 decreased cell growth both in parental and resistant cells, which was rescued by enforced expression of wild-type BRD4 (Fig. 3c ). BDmut BRD4 expression failed to rescue parental SUM159 cells, but supported growth of JQ1-resistant SUM159R consistent with an evident bromodomain-independent mechanism of BRD4 recruitment (Fig. 3c ). Next, we assessed the sensitivity of cells expressing BDmut BRD4 to JQ1, observing increased sensitivity to JQ1 in parental SUM159 cells exogenously expressing BDmut (Fig.  3d ). In contrast, expression of BDmut BRD4 in SUM159R cells rescued the anti-proliferative effect of JQ1 ( Fig. 3e ), although this could partially be due to the slower growth of BDmut expressing cells. Together, these studies suggest that BBI-resistance is associated with increased binding of BRD4 to MED1, in a bromodomain-independent manner unaffected by JQ1.
A recent study reported that the stability and nuclear localization of BRD4 is increased with phosphorylation by casein kinase II (CK2) 21 . To explore the contribution of BRD4 phosphorylation to BBI-resistance, we performed immunoblot analysis in parental and resistant cells and found a marked increase of phospho-BRD4 (pBRD4) in resistant cells ( Fig. 4a and Extended Data Fig. 8d ). Small-molecule inhibition of CK2 decreased BRD4 phosphorylation in SUM159 and SUM159R cells (Extended Data Fig. 8e ). These results imply BRD4 hyperphosphorylation in resistant cells either owing to increased phosphorylation by CK2 or, alternatively, to decreased dephosphorylation by an as yet unidentified BRD4 phosphatase. We therefore first analysed CK2 activity in parental and resistant cells by performing pan-CK2 substrate immunoblots and detected no significant differences in CK2 activity (Extended Data Fig. 8f ). 
Inactivation of the PP2A phosphatase tumour suppressor gene occurs commonly in breast cancer and is associated with therapy resistance 22 ; PP2A also often opposes CK2 function 23, 24 . Thus, we investigated whether PP2A may dephosphorylate BRD4 and whether decreased PP2A activity could lead to BBI resistance. Downregulation of PP2A catalytic subunit (PPP2CA) in SUM149 and SUM159 cells led to increased BRD4 phosphorylation, establishing PP2A as a previously unrecognized BRD4 phosphatase ( Fig. 4b ), further supported by pharmacologic inhibitors of PP2A that showed similar effects (Extended Data Fig. 8g ). To strengthen the link between PP2A activity and BBI resistance, we tested the JQ1 sensitivity of SUM149 cells following the knockdown of PP2A C subunit and determined that downregulation of PP2A decreased JQ1 sensitivity ( Fig. 4c ). We have collaboratively reported phenothiazine compounds as activators of PP2A enzymatic activity 25 . Thus, we analysed pBRD4 levels in SUM159R, SUM149R and other cell lines after short-term treatment with phenothiazine (PTZ) and detected rapid dephosphorylation of BRD4 ( Fig. 4d and Extended Data Fig. 8h ). Combined treatment with PTZ and JQ1 overcame BBI resistance in SUM159R cells ( Fig. 4e ). To investigate the functional role of BRD4 hyperphosphorylation in BBI resistance, we analysed whether BRD4 phosphorylation influences MED1 binding. Indeed, SUM159R cells treated with CK2 inhibitor or PTZ both lead to decreased MED1 abundance in BRD4 immunoprecipitations, suggesting that pBRD4 binds MED1 more efficiently than BRD4 ( Fig. 4f, g) .
To functionally assess the role for BRD4 phosphorylation in BBI resistance and MED1 binding, we generated BRD4 constructs encoding mutants that cannot be phosphorylated by CK2 (7 serine to alanine substitutions; '7A mutant') or mimic constitutive phosphorylation (7 serine to aspartate substitutions; '7D mutant'). We first assessed the ability of these constructs to rescue effects of endogenous BRD4 knockdown in stable cell lines (Extended Data Fig. 8b, c) . We observed expression of both 7D and 7A mutants supporting the growth of both parental SUM159 and JQ1-resistant SUM159R cells ( Fig. 3c ). Next, we analysed MED1 binding and subcellular localization of 7A and 7D mutants in the presence or absence of JQ1. We found that the 7A mutant displays weaker MED1 binding compared to wild-type BRD4 and completely dissociates after JQ1, whereas the 7D mutant seems to have higher affinity for MED1 that is unaffected by JQ1 treatment ( Fig. 4h and Extended Data Fig. 8i ). Lastly, we assessed the sensitivity of cells expressing 7A or 7D mutant BRD4 to JQ1. In parental SUM159 cells exogenously expressed 7D mutant BRD4 decreased sensitivity to JQ1, whereas the 7A mutant slightly increased sensitivity (Fig. 4i ). In contrast, expression of 7A mutant BRD4 in SUM159R cells restored JQ1 sensitivity, whereas the 7D mutant showed a modest decrease. These results strongly support the hypothesis that hyperphosphorylation of BRD4 arises from decreased PP2A activity in BBI resistant cells, leading to increased binding of BRD4 to MED1, recruitment to chromatin and decreased responsiveness to bromodomain inhibition.
To explore the clinical relevance of phospho-BRD4 (pBRD4) in BET inhibitor-naive TNBC, we performed immunofluorescence analysis of a tissue microarray (TMA) featuring of 89 patient-derived TNBC specimens. First, we validated the pBRD4 immunofluorescence assay by comparing xenografts derived from SUM159 and SUM159R cell lines and detected significantly higher pBRD4 in SUM159R cells (Extended Data Fig. 9a ). We detected strong pBRD4 staining among a subset of TNBCs (Extended Data Fig. 9b , c), and variable staining overall that was not correlated with expression of the androgen receptor and basal cytokeratins (bCK; Extended Data Fig. 9d , e) and it was not significantly associated with disease outcomes (Supplementary Table 9 and Extended Data Fig. 9f ).
To extend the translational relevance of our findings, we conducted synergy studies of JQ1 with molecules targeting BCL-xL (ABT737), a gained super-enhancer in SUM159R cells, and modulators of BRD4 phosphorylation, the CK2 inhibitor CX-4945 and the PP2A activator perphenazine (PPZ). We observed significant synergy between JQ1 and all three compounds studied (Extended Data Fig. 10 ), establishing a rationale for combination studies of BBI in TNBC to improve response and to anticipate BBI resistance.
BRD4 inhibition has demonstrated efficacy in disparate models of cancer in a rapidly expanding literature. Despite apparent resistance in the vast majority of tumour types, as we observed here in TNBC, mechanisms of BBI-resistance have not been mechanistically explained. As this research was in review, two studies reported moderate emergent resistance to BBI in murine AML associated phenotypically with a stem-like state and WNT pathway activation 26, 27 . Interestingly, in our study TNBCs with more basal/stem cell-like features and WNT pathway activation are more sensitive to BET inhibition, whereas resistant disease emerges as epigenomic adaptation to a more differentiated luminal phenotype. Our findings of persistent BET bromodomain dependency despite BBI resistance, as well as pBRD4 staining in All error bars represent s.d., n = 3. a, Immunoblot for the indicated proteins following JQ1 treatment. b, Immunoblot for the indicated proteins after knockdown of PP2A A or C or both subunits. c, Viable cell numbers of JQ1-treated control and shPP2A-C expressing SUM149 cells. Left, *P < 0.0001 (two-way ANOVA); right, *P = 0.0037and **P = 0.0015 (two-way ANOVA). d, Immunoblot of pBRD4 and BRD4 in SUM159R cells following phenothiazine (PTZ) treatment. e, Viable cell numbers of SUM159R cells treated with JQ1, phenothiazine or both compounds. *P < 0.0001 (two-way ANOVA). f, g, Immunoblot of BRD4 immunoprecipitates and total cell lysates of SUM159R cells after 3 h treatment with JQ1 and CK2i (f) and JQ1 and PTZ (g). h, Immunoblot of Flag-BRD4 (wild type or mutant) immunoprecipitates and total cell lysates after 3 h treatment with JQ1. i, JQ1 sensitivity of SUM159 and SUM159R cells expressing exogenous wild-type or mutant (7A, 7D) BRD4. *P < 0.0001 (non-linear regression, extra sum-of-squares test). For gel source data, see Supplementary Fig. 1 .
Letter reSeArCH resistant disease, should be studied in these murine AML models and further in human leukaemia.
Integrating approaches in epigenomics, proteomics and chemical biology, we provide an example of epigenomic drug resistance by an epigenetic mechanism, where in BBI-resistant cells, decreased PP2A activity leads to hyperphosphorylated BRD4, which binds more strongly to MED1, facilitating a bromodomain-independent chromatin recruitment mechanism. This research proposes putative combination strategies to anticipate and overcome BBI resistance, including pairing with BCL-xL inhibitors (for example, ABT-737) or CK2 inhibitors, and guides the development of second-generation BBIs that disrupt BET function via orthogonal biophysical or biochemical actions. More immediately, the robust efficacy observed in pre-clinical models supports the development of BET inhibition in TNBC alone, and in combination with mechanism-based targeted therapies.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Published online 6 January 2016.

MethODS
No statistical methods were used to predetermine sample size. The experiments were not randomized, and the investigators were not blinded to allocation during experiments and outcome assessment. Cell lines and breast tumour tissues. Breast cell lines were obtained from the ATCC and S. Ethier (SUM series). Cells were cultured in media recommended by the provider, their identity was confirmed by STR analysis, and they were regularly tested for mycoplasma. Breast tumour samples were collected using protocols approved by the DF/HCC Institutional Review Board, informed consent was obtained from all patients. Tumours were minced with razor blades and digested with stirring for 3-4 h at 37 °C in DMEM/F12 with 2 mg ml −1 BSA, 2 mg ml −1 collagenase type IV, and 2 mg ml −1 hyaluronidase. After digestion, cells were filtered through 500-μm mesh, washed in DMEM/F12 with 5% FBS, frozen in DMEM/ F12 with 5% FBS and 10% DMSO, and stored in liquid nitrogen for subsequent xenograft studies. PDX IDC50 was derived from a primary tumour of highly invasive metaplastic TNBC resistant to chemo and radiation therapy leading to the rapid death of the patient. Exome sequencing of the tumour and xenograft identified numerous mutations including heterozygous frameshift mutation in PTEN (chr10_89701964-89701964_A) and CDH1 chr16_67400242-67400242_C). PDX EL-12-58 was derived from a liver metastasis of a heavily pretreated basal-like TNBC, Oncopanel mutation testing identified homozygous mutations in BRCA2 (p.S1970*), TP53 (p.I232fs), TSC2, FLT3, and ROS1, and lower frequency mutations in RAD21, JAK3, ARID1B, ARID1A, KDM6A.
High-throughput screening of BET bromodomain inhibitors in breast cell line panel.
We tested a panel of compounds (synthesized in the Bradner laboratory) in 40 human breast cell lines in a 384-well format at 2,000 cells per well using a semi-automated screen essentially as described 5 . Cell viability at 72 h was evaluated using ATPlite (Perkin Elmer). Synergy studies. SUM149, SUM149R, SUM159, and SUM159R cells were seeded in sterile, white, opaque 384-well microtitre plates (Thermo), using an automated dispensing system (BioTek EL406), at 1,000 cells per well in 50 μl of media. Drugs were delivered in DMSO by robotic pin transfer with a JANUS workstation (100 nl) to achieve a matrix of pairwise dose-response incubations of each compound, each pair having eight replicates. Following 72 h of incubation, ATP levels were determined for treated cells and vehicle controls (ATPlite, PerkinElmer). Data were normalized to vehicle controls. Combination indices were determined using the median-effect principle of Chou & Talalay 28 (CalcuSyn Software). Isobologram plots were generated with GraphPad Prism software. Points represent paired values of drug concentrations assessed for synergism. The diagonal line signifies drug additivity. Points above the line represent antagonistic drug combinations, and those below the line represent synergistic drug combinations. Synergy assays were performed in triplicates and repeated 2-3 times. Xenograft assays. For xenograft assays 5-6-weeks old female CrTac:NCr-Foxn1 nu and NOD.Cg-Prkdc scid Il2rg tm1Sug /JicTac mice were purchased from Taconic. Tumours were induced by bilateral orthotopic mammary fat pad injection of 1 × 10 6 cells in 50% Matrigel (BD Biosciences) in DMEM/F12 or Medium 171 (except for IDC50-X cells, which were injected with 3% FBS and 4 mg ml −1 collagen gel in Medium 171). Animal experiments were conducted following protocol 11-023 approved by the Dana-Farber Cancer Institute Animal Care and Use Committee. For all the xenograft studies, the sample size of each group (5-10 mice) is indicated in the figures. We performed pilot experiments using a few (5-10) mice per group followed by larger studies if needed to reach statistical significance and repeated experiments to ensure reproducibility. Due to the nature of the performed experiments, no randomization and no blinding was used as it was deemed unfeasible. However, the resulting tumours were analysed in a blinded manner. Mice were administered JQ1 (50 mg per kg, daily), vehicle only (control) for 14 days beginning at day 14 (SUM159), or doxycycline at day 21 (SUM159-shBRD4) after injection. Mice were euthanized and tumours evaluated 28 and 60 days after injection of parental and TET-inducible shBRD4-expressing SUM159 cells into mammary fat pads. Cellular viability, senescence, MDR and BH3 profiling assays. Cell viability and growth assays (Figs 1a, 2a , b, 3d, e, 4c, i, Extended Data Figs 1a, b, 3i, 4d, e, g, h, 10), cycle, apoptosis, and MDR assays were performed in triplicates and repeated 2-3 times. For cell proliferation assays, cells were plated at 500 cells per well in 96-well plates and treated the next day with inhibitors, DMSO or doxycycline (500 ng). Cells were cultured at 37 °C with 5% CO 2 in the media described above, and cell viability was measured using CellTiter-Glo three days after treatments. For cell growth assays, cells were plated at 5,000 (SUM159) or 20,000 (SUM149) cells per well in 6-well plates and treated the next day with inhibitors. Cells were counted every three days by cell counter. Cellular apoptosis was analysed with an APC AnnexinV/7ADD Apoptosis Detection kit (BD Pharmingen). AnnexinV/7AAD assessments and cell cycle graphics were generated using FlowJo software V7.6.1 for Windows (Tree Star). Senescence Beta-gal staining was performed using Senescence β-Galactosidase staining kit from Cell Signaling. Briefly, after JQ1 treatment (500 nM) for 72 h, SUM159 and MDA-MB-231 cells were fixed by fixative solution for 15 min, followed by β-galactosidase solution incubation overnight at 37 °C. The staining was checked under microscope for the development of blue colour. Multi-Drug Resistance Assay was performed with MDR assay kit from Cayman Chemical (600370). Briefly, SUM159 and SUM159R cells were treated with JQ1 or DMSO for 30 min in SUM medium. Verapamil was used as a positive control at 1:1,000 dilution. Calcein AM/Hoechst Dye staining solution was added after that and cells were incubated at 37 °C for 15 min. The cells were analysed by fluorescent microscope and FACS.
Cell cycle analysis was performed 72 h after JQ1 treatment or BRD4 downregulation with doxycycline using propidium iodide (PI) staining. Cells were resuspended in 1 ml of growth medium supplemented with 2 μg ml −1 PI (Life Technologies) as final concentration. After 60 min at 37 °C in the dark, analysis was performed on a FACS AriaII cytometer (BD Biosciences). The cell cycle was plotted as histogram after excluding doublets. Cell synchronization procedure. SUM159 cells were treated with nocodazole (200 ng ml −1 ) for 12 h and then cells were tapped to detach from the plates. After washing twice with PBS, cells were replated with or without JQ1 in collagen-coated plates. Cells were collected at 0, 3, 6, 12 h time point for FACS and immunoblot analysis. Dynamic BH3 profiling was performed using the JC-1 plate method as previously described 18, 19 . Briefly, 2.5 × Best blocks and best areas for coring were identified and selected by a breast pathologist (DD) to represent different area of the tumour. Results of immunohistochemical studies for oestrogen (ER) and progesterone receptor (PR) and HER2 and FISH assay results for HER2 were extracted from pathology reports. TMA construction was carried out in the Dana-Farber/Harvard Cancer Center Tissue Microarray Core Facility. Three 0.6 mm cores were taken from different marked areas in each case and placed into a recipient block using a manual arrayer (Beecher Instruments). Specimens are arrayed in triplicate. Participants signed consent for research use of tissue and the linking of tumour specimens to clinical follow-up. Clinical data on these patients was collected retrospectively at first presentation, at 4, 9, 18, 30 , and 42 months, and annually thereafter. After 9.3 years median follow up, 24 recurrences and 14 deaths have been recorded. The data elements are the following: staging, tumour pathology, diagnostic and follow-up tests performed, treatments administered (surgery, radiation and systemic therapy), and recurrence. Although the patients in this cohort were not treated as part of a clinical trial protocol, they were treated relatively uniformly as per Dana-Farber clinical practice guidelines. This serves to minimize confounding due to treatment heterogeneity. The TMA was stained with pBRD4 (1:200) antibody and imaged manually on Yokagawa spinning disc confocal microscope.
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Three images were taken per each core for 240 out of 267 cores, for the remaining 27 one or two images were taken due to tissue loss or low tumour content. Image analysis was performed with ImageJ software macro (code available upon request). Phospho-BRD4 staining mean intensity was calculated per individual nucleus within an image. The mean intensity per image was normalized to nuclei count. For clinical outcome analysis patients were dichotomized as 'High'/'Low' pBRD4 by median intensity ( Supplementary Table 9 ). Disease outcomes were evaluated in 83 of 89 TMA samples (3 were not TNBC by definitive pathology, 2 did not have clinical data available, one was a repeat biopsy on a patient). Recurrence-free survival (RFS) was defined as the interval from the date of initial surgical resection to the date of recurrence (local or distant), or date of last known contact if the patient was alive and has not recurred. RFS and overall survival were estimated using the Kaplan-Meier product-limit method, with hazard ratios and 95% confidence intervals from a univariate Cox proportional hazard model. siRNAs and lentiviral shRNA and expression constructs. For siRNA transfection cells were plated at 2,000 cells per well in 96-well plates and cultured at 37 °C with 5% CO2 in the media. The next day, cells were transfected in triplicate with siGENOME SMARTpools for the genes of interest or "Non-Targeting siRNA" controls using DharmaFECT 1 (Dharmacon). The sequences of the siRNAs in the SMARTpools are listed in Supplementary Table 10 . Cell viability was measured using CellTiter-Glo (Promega) three days after transfections, with the effects of each siRNAs treatment on each cell line compared to the effects of no siRNAs.
TET-inducible pLKO-TET-ON lentiviral constructs were packaged by co-transfection of the lentiviral hairpin containing plasmid PLKO.1 and the helper plasmids pCMV-dR8.91 and pMD2.G-VS.V-G into HEK293T cells using Lipofectamine (Life Technologies). Following transduction via spinoculation for 30 min at 1,000g and selection with 1 μg ml −1 puromycin for 72 h (Sigma, St. Louis, MO), knockdown efficacy was determined by western blotting and cells were seeded for proliferation assays as described above. Sequences of shRNAs used are listed in Supplementary Table 10 .
Full length BRD4 in pCDNA3 was a gift from Dr. French at Brigham and Women's Hospital, Harvard Medical School. Mutations of BRD4 BD1 (N140A) and BD2 (N433A) bromodomains, 7A and 7D mutants were generated using a Quickchange Multi Site-Directed Mutagenesis Kit (Agilent Technologies) using primers listed in Supplementary Table 10 and subsequently verified by sequencing. Immunoblotting and immunoprecipitation experiments. Cells were lysed five days after transfection with siRNAs in RIPA buffer. Proteins were resolved in SDS-polyacrylamide gels (4-12%) and transferred to PVDF membranes by using a Tris-glycine buffer system. Membranes were blocked with 5% milk powder in 0.1% Tween20 in PBS (PBS-T) for 1 h at room temperature followed by incubation with primary antibodies at 1:1,000 dilution in 2.5% milk PBS-T. For immunoprecipitation, nuclear extracts were prepared as follow: 1 × 10 7 cells were resuspended in 5 ml buffer A: 10 mM Tris pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.05% NP-40, 1 mM DTT, and protease and phosphatase inhibitors. Cells were incubated on ice for 15 min and gently vortexed every 5 min. After centrifugation at 2,000g for 5 min, pellets were suspended in 0.3 ml buffer B (20 mM Tris pH 7.9, 25% glycerol, 0.42 M NaCl, 1.5 mM MgCl 2 , 1 mM KCl, 0.5% NP40, 0.2 mM EDTA, 1 mM DTT, and protease and phosphatase inhibitors) and incubated for 5 min on ice. After centrifugation of the lysates at 14,000g for 10 min at 4 °C, supernatant was diluted with 0.6 ml buffer A, and added NP-40 to final 0.5% and treated with DNase I. The samples were then incubated at 4 °C overnight with BRD4 or Flag antibodies at 1:100 dilution and immunoprecipitates were collected on Dynabeads Protein G for 2 h. Beads were washed with buffer B containing 150 mM NaCl and 0.5% NP-40 three times and then resuspended in gel loading buffer. Immunoblotting and immunoprecipitation experiments were repeated 2-3 times. Antibodies and inhibitors. Antibodies used for immunoblotting, immunoprecipitation and ChIP-seq were as follows: BRD4 (Bethyl, A301-985A), MED1 (Bethyl, A300-793a), BRD3 (Bethyl, A302-368A), BRD2 (Bethyl, A302-583A), MYC (Santa Cruz, sc764), pSTAT3 (Cell Signaling, 9145S), STAT3 (Cell Signaling, 4904), pSTAT5 (Cell Signaling, 9351), pJAK2 (Cell Signaling, 3771), CYCLIN D1 (Cell Signaling, 2922), pH3 (Cell Signaling, 12201), CK2 substrate (Cell Signaling, 8738), PP2A-A (Cell Signaling, 2039), PP2A-C (Cell Signaling, 2038) and pBRD4 was a gift from C. M. Chiang. Antibodies used for ChIP-seq were BRD4 (Bethyl) histone H3K27ac (Abcam, ab4729). CXCR2 inhibitor (239819) and CK2 inhibitor (218860) were from CalBiochem, JAK2 inhibitor (Ruxolitinib, INCB018424), MEK inhibitor (GSK1120212, S2673), ABT-737 (s1002), and PI3K inhibitor (BKM120, S2247) were from Selleckchem, phenothiazine (1525707) and perphenazine (1511000) were from Sigma-Aldrich. Inhibitor treatment for immunoblot analyses was conducted for 3 h. SILAC-RIME experiments and data analysis. SUM159 and SUM159R cells were grown in R/K-deficient SILAC DMEM (paa; E15-086), 10% dialysed serum (Sigma-Aldrich; F0392), and supplemented with 800 μM l-lysine 13 C 6 15 N 2 hydrochloride and 482 μM l-arginine 13 C 6 15 N 4 hydrochloride (Cambridge Isotope laboratory) for 'heavy'-labelled media or 800 μM l-lysine 12 C 6 14 N 2 -hydrochloride and 482 μM l-arginine 12 C 6 14 N 4 hydrochloride for 'light'-labelled media. After SILAC labelling, RIME was performed as described 20 . Word clouds for Extended Data Fig. 7 were generated using R version 3.1.0 and the R package 'wordcloud' version 2.5. The size of the tag reflects the square root of the MASCOT score of the protein (the choice of square root is arbitrary, but visually appealing). Experiments were filtered against the Contaminant Repository for Affinity Purification Mass Spectrometry Data 30 , considering any protein which occurs in at least 20 negative control experiments to be contamination, hence removed from the data set. Refseq protein IDs provided by the contaminant repository were converted to Uniprot IDs found in the mass spec experiments using mappings from the Bioconductor package 'org.Hs.eg.db' , version 2.14 (Carlson M. org.Hs.eg.db: Genome wide annotation for Human. R package version 3.0.0). SILAC RIME experiments were performed in duplicates and repeated 2-3 times. In vitro Chem-seq, ChIP-seq, and RNA-seq. Chem-seq was performed essentially as described 11 . BRD4 ChIP-seq: SUM159 and SUM159R cells (4 × 10 7 ) were grown in SUM Medium. The media were then removed and replaced with media containing 1% formaldehyde (EM grade; tebu-bio) and crosslinked for 8 min. Crosslinking was quenched by adding glycine to a final concentration of 0.2 M. The cells were washed with ice-cold PBS, harvested in PBS, and the cell pellet was washed with PBS. The nuclear fraction was extracted by first resuspending the pellet in 10 ml of LB1 buffer (50 mM HEPES-KOH (pH 7.5), 140 mM NaCl, 1mM EDTA, 10% glycerol, 0.5% NP-40 or Igepal CA-630, and 0.25% Triton X-100) for 10 min at 4 °C. Cells were pelleted, resuspended in 10 ml of LB2 buffer (10 mM Tris-HCL (pH 8.0), 200 mM NaCl, 1 mM EDTA, and 0.5 mM EGTA), and mixed for 5 min. Cells were pelleted and resuspended in 300 μl of LB3 buffer (10 mM Tris-HCl (pH 8), 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na-deoxycholate, and 0.5% N-lauroylsarcosine) and sonicated in a Covaris sonicator for 10 min. A total of 30 μl of 10% Triton X-100 was added, and lysate was centrifuged for 10 min at 20,000 rcf to purify the debris. The supernatant was then incubated with 100 μl of Dynabeads Protein G (Life Technologies, 10003D) prebound with 20 μg BRD4 antibody (Bethyl, A301-985A), and immunoprecipitation (IP) was conducted overnight in the cold room. The beads were washed ten times in 1 ml of RIPA buffer and twice in 100 mM ammonium hydrogen carbonate (AMBIC) solution. DNA was eluted in elution buffer (50 mM Tris-HCl pH 8, 10 mM EDTA, and 1% SDS). Cross-links were reversed overnight at 65 °C. RNA and protein were digested with 0.2 mg ml −1 RNase A for 2 h followed by 0.2 mg ml −1 Proteinase K for 1 h. DNA was purified with phenol-chloroform extraction and ethanol precipitation. Libraries for Illumina sequencing were prepared following the Rubicon ThruPLEX-FD kit for 10-12 cycles.
RNA-seq: SUM159 and SUM159R were incubated in biological duplicates for 3, 12 and 24 h with 500 nM of JQ1 or DMSO treatment. Total RNA was extracted using the standard Qiagen RNeasy kit (74106). RNA concentrations were measured and quality controlled on a Bioanalyzer, RNA-Seq libraries were made using Illumina True-Seq RNA kits using the Sciclone NGSx workstation.
All RNA-seq and ChIP-seq experiments were performed in duplicates. Genomic data analyses. Accessing data generated in this manuscript. All ChIP-seq, Chem-seq, and RNA-seq data generated in this publication can be found online associated with GEO Publication Reference ID GSE63584 (www.ncbi.nlm.nih.gov/ geo/). Supplementary Table 2 lists all sequencing data sets and their corresponding GEO GSM accession IDs. Gene sets and annotations. All analysis was performed using RefSeq (NCBI37/ HG19) human gene annotations. RNA-seq data processing and gene expression quantification. All RNA-Seq data sets were aligned to the transcriptome using Tophat2 31 (version 2.0.11) using the Illumina igenomes NCBI37/HG19 UCSC transcriptome build retrieved from http://ccb.jhu.edu/software/tophat/igenomes.shtml. Alignments were performed using default parameters. Transcript expression quantification was performed using Cufflinks 32 (version 2.2.0) with default parameters to generate gene expression values in units of FPKM. ChIP-seq and Chem-seq data processing. All ChIP-seq and Chem-seq data sets were aligned using Bowtie2 33 (version 2.2.1) to build version NCBI37/HG19 of the human genome or build version NCB37/MM9 of the mouse genome. Alignments were performed using the following criteria: -k 1, with all other parameters set to default. These criteria preserved only reads that mapped uniquely to the genome without any mismatches. Calculating read density. We calculated the normalized read density of a ChIPseq or Chem-seq data set in any region using the Bamliquidator (version 0.9) read density calculator (https://github.com/BradnerLab/pipeline/wiki/ bamliquidator). Briefly, ChIP-Seq reads aligning to the region were extended by 200 bp and the density of reads per base pair (bp) was calculated. The density of reads in each region was normalized to the total number of million mapped Letter reSeArCH reads producing read density in units of reads per million mapped reads per bp (rpm per bp). Identifying ChIP-seq and Chem-seq enriched regions. We used the MACS version 1.4.2 (Model based analysis of ChIP-Seq) 34 peak finding algorithm to identify regions of ChIP-Seq enrichment over background. A P value threshold of enrichment of 1 × 10 −9 was used for all data sets. The GEO accession number and background used for each data set can be found in the accompanying Supplementary  Table 2 .
Creating heat map representations of ChIP-seq occupancy. Heat maps of ChIP-seq occupancy for various factors were created as described 35 . Heat maps were created for the ±10 kb region flanking all transcription start sites (TSS) or for the ±10 kb region flanking all TSS distal BET bromodomain bound enhancers. Each row plots a specific TSS or enhancer region. Rows are ranked by peak occupancy of BET bromodomains as determined by Bio-JQ1 Chem-seq signal (Fig. 1d) . Correlating BRD4 and H3K27ac occupancy to Bio-JQ1. Occupancy of BRD4 and H3K27ac was correlated to Bio-JQ1 occupancy at all regions of Bio-JQ1 enrichment in SUM159 cells. Pearson correlation statistics are shown (Extended Data Fig. 3a ). To quantify changes in BRD4 or H3K27ac occupancy upon JQ1 treatment, all Bio-JQ1 enriched regions were ranked in SUM159 cells and then binned (n = 10). Corresponding box plots of BRD4 or H3K27ac log 2 fold change with or without JQ1 are shown for each bin (Extended Data Fig. 3b ). Mapping enhancers and super-enhancers using Bio-JQ1 occupancy or BRD4. Enhancers and super enhancers (SEs) were mapped using the ROSE software package described 12, 13 and available at (http://younglab.wi.mit.edu/super_enhancer_ code.html). In SUM159 and SUM159R cells, Bio-JQ1 Chem-Seq enriched regions were used to map enhancers and super enhancers (Fig. 1f ). In SUM149 cells, BRD4 ChIP-seq enriched regions were used to map enhancers and super enhancers (Extended Data Fig. 3a ). Enhancers are defined as regions of Bio-JQ1 binding not contained in promoters.
Quantifying changes in gene expression of super enhancer proximal genes. Genes within 50 kb of super enhancer in SUM159 or SUM149 were identified and filtered for expression status (>1 FPKM expression in any sample), and filtered to remove non poly-adenylated transcripts (for example, microRNAs). For SUM159, log 2 fold changes in gene expression at super-enhancer-associated genes or all expressed genes was compared at 3, 12, and 24 h post JQ1 treatment (Fig. 1g ). For SUM149, comparisons were made at 12 h post JQ1 treatment (Extended Data Fig. 3f ). The statistical significance of differences between distributions of changes was also assessed using a Welch's two-tailed t test. Identifying differentially expressed genes upon JQ1 treatment. To identify genes differentially regulated by JQ1 treatment in SUM159 or SUM149 cells, all genes with a >1 log 2 fold change in expression were ordered by fold change at 24 h with or without JQ1 for SUM159 or at 12 h with or without JQ1 for SUM149. The log 2 row median normalized fold change for each gene is displayed as a heat map in Extended Data Fig. 3g for SUM159 and in Extended Data Fig. 3h for SUM149. For subsequent gene set and pathway analysis, SUM159 genes with consistent and statistically significantly altered expression were selected using a Welch's two-tailed t test between DMSO and JQ1 treated expression values at 12 and 24 h. A P value cut-off of 0.01 was applied (Extended Data Fig. 3k ).
Identifying gained/lost super enhancers between SUM159 and SUM159R. Super enhancer differential regions were defined as in Brown et al. 2014 36 . Briefly, in order to quantify changes in super-enhancers between two conditions, background subtracted ChIP-Seq signal was calculated at the set of all enhancer regions considered super in at least one condition. Gained/lost super-enhancers were determined as those with a greater than log 2 fold change signal in either direction. The log 2 fold change in Bio-JQ1 occupancy at all rank ordered super-enhancer-containing regions is shown in Fig. 2c . Super enhancer regions were classified as either gained, conserved, or lost. Gained/lost regions were classified as those with >1 log 2 fold change in either direction. Conserved regions were classified as those with <0.25 log 2 fold change in either direction. The log 2 fold change in either BRD4 or proximal (within 50 kb of region) gene expression is shown in Extended Data Fig. 5d-f . Quantifying changes in BRD4 and H3K27ac occupancy upon JQ1 treatment in either SUM159 or SUM159R cells at Bio-JQ1 regions. Log 2 fold changes in BRD4 or H3K27ac were quantified at Bio-JQ1 enriched regions in their respective cell line and shown in Extended Data Fig. 5c . Quantifying changes in BRD4 and H3K27ac as a function of Bio-JQ1 or BRD4 occupancy. Bio-JQ1 enriched regions in SUM159 or BRD4 enriched regions in SUM149 were ranked by increasing levels and then distributed into 10 bins. Log 2 fold changes in BRD4 or H3K27ac were quantified in each bin of regions and displayed as a box plot (Extended Data Fig. 3b, c) . Quantifying changes in BRD4 occupancy upon JQ1 treatment in all TNBC. Log 2 fold changes in BRD4 upon JQ1 treatment were quantified at BRD4 enriched regions in each respective cell line Extended Data Fig. 6c .
All code related to genomic and transcriptome analysis can be found at https:// github.com/BradnerLab/TNBC.
Extended Data Figure 1 | BET bromodomain proteins and cell growth in TNBCs. All error bars represent s.d., n = 3. a, Cellular viability of SUM159 and MDA-MB-231 cells expressing TET-inducible BRD4targeting or lacZ shRNAs. P values indicate statistical significance of the observed differences (paired t-test). b, Cellular viability four days after transfection of siRNAs targeting BET bromodomain proteins. Asterisks indicate statistical significance (paired t-test) of the marked differences as follows. SUM159: siBRD2 versus siBRD3, P = 0.002; siBRD3 versus siBRD4, P = 0.0006, MDA-MB-231: siBRD2 versus siBRD3, P = 0.006; siBRD2 versus siBRD4, P = 0.002; siBRD3 versus siBRD4, P = 0.016, MDA-MB-468: siBRD2 versus siBRD3, P = 0.0009; siBRD3 versus siBRD4, P = 0.0055, MDA-MB-436: siBRD2 versus siBRD4, P = 0.002; siBRD3 versus siBRD4, P = 0.015, ZR-75-1: siBRD2 versus siBRD3, P = 0.0169; siBRD3 versus siBRD4, P = 0.007. c, Immunoblot analysis of BET bromodomain proteins four days after siRNA transfection. d, Cell cycle profile of SUM159 cells synchronized in G2/M with 100 ng ml −1 nocodazole followed by replating to fresh medium with DMSO or JQ1 (500 nM) added at −1 h or at 3 h after release. Cells were collected at different time points (0, 6, 12 h) after release. e, Immunoblot analysis of the indicated proteins at different time points (0, 3, 6, 12 h) after release of SUM159 cells synchronized with 100 ng ml −1 nocodazole followed by replating to fresh medium with DMSO or JQ1 (500 nM) added at 1 h before or 3 h after release. f, Cell cycle analysis of SUM159 cells following 72 h treatment with JQ1 (500 nM) or downregulation of BRD4 using TET-inducible shRNAs. g, Annexin V staining of SUM159 cells following 72 h treatment with JQ1 (500 nM) downregulation of BRD4 using TET-inducible shRNAs. All error bars represent s.e.m. h, Immunoblot analysis of the indicated proteins in a panel of breast cell lines; colour scheme as in a. For gel source data, see Supplementary Fig. 1 . implanted with pieces of tissue measuring 1 × 3 × 3 mm into the inguinal mammary fat pads and were administered daily JQ1 (50 mg per kg) for 14 days beginning at day 21 after injection (after tumours reached palpable size). f, Bromodeoxyuridine (BrdU) and luminal (Low MW CK) and basal high (High MW CK) molecular weight cytokeratin staining of EL12-58 xenograft with or without JQ1 treatment. Scale bars, 50 μm. g, Tumour volume of SUM159 cells expressing TET-inducible BRD4-targeting shRNAs. Mice were administered doxycycline or vehicle only (control) for 39 days beginning at day 21 after injection (after tumours reached palpable size). Error bars represent s.d., n = 4 (shBRD4-1 experiment) and n = 5 (shBRD4-2 experiment). h, Haematoxylin and eosin staining and immunofluorescence analysis of basal (basal cytokeratin, cytokeratin 17, pSTAT3, and CD44) and luminal (luminal cytokeratin, cytokeratin 18, and CD24) markers in SUM159 xenografts with or without JQ1 treatment. Scale bars, 100 μm for haematoxylin and eosin and 50 μm for immunofluorescence, respectively. For gel source data, see Supplementary  Fig. 1 .
Extended Data Figure 4 | Characterization of SUM159R cells. a, Expression of ABC transporters in SUM159 and SUM159R cells. The expression of 29 ABC transporters was analysed based on RNA-seq data on the two cell lines. b, Assay for MDR (multi drug resistance) pumps in SUM159 and SUM159R cells treated with JQ1 alone or together with verapamil based on microscopic examination (left) and FACS (right) of cells labelled with fluorescent MDR substrate. c, Immunoprecipitation analysis of Biotinylated JQ1 (Bio-JQ1) in SUM159 and SUM159R cells with JQ1 treatment at different time points following immunoblot for the indicated proteins. d, Cellular viability of SUM159 and SUM159R cells treated with CXCR2 and JAK2 inhibitors. Error bars represent s.d., n = 3. e, Cellular viability of SUM159, and pool and single cell clones of SUM159R cells treated with different doses of JQ1. Error bars represent s.d., n = 3. f, Tumour weight of xenografts derived from SUM159 and SUM159R cells. Mice were administered JQ1 for 14 (SUM159) and 30 (SUM159R) days beginning at day 14 and 26, respectively, after injection. P values indicate statistical significance of the observed differences (unpaired t-test). Error bars represent s.e.m. g, Immunoblot analysis of BCL-XL expression in SUM159 and SUM159R cells before and after JQ1 3 h treatment (500 nM). h, Dynamic BH3 profiling reveals inverse apoptotic response to JQ1 in SUM149R and SUM159R cells. In parental lines JQ1 increases priming relative to untreated cells indicating an increase in apoptotic propensity. In resistant lines JQ1 reduces priming indicating greater resistance to apoptosis relative to untreated cells. P values indicate statistical significance of the observed differences (two-way ANOVA). Error bars represent s.e.m., n = 5. For gel source data, see Supplementary Fig. 1 .
Extended Data Figure 5 | BRD4 binding in SUM159R cells. a, Cellular viability of SUM159 and SUM159R cells transfected with siRNAs targeting bromodomain proteins. Asterisks indicate statistical significance (paired t-test) of the marked differences as follows: SUM159: siBRD2 versus siBRD3, P = 0.013, siBRD3 versus siBRD4, P = 0.0154 and SUM159R: siBRD2 versus siBRD3, P = 0.0159, siBRD2 versus siBRD4, P = 0.0048; siBRD3 versus siBRD4, P = 0.0068 
